Real-World Outcomes of Idecabtagene Vicleucel in relapsed/refractory Multiple Myeloma: Comparative Analysis of Genetically and Clinically Defined High-Risk Versus Standard-Risk Patients from the CIBMTR Registry | Synapse
March 3, 2026
Real-World Outcomes of Idecabtagene Vicleucel in relapsed/refractory Multiple Myeloma: Comparative Analysis of Genetically and Clinically Defined High-Risk Versus Standard-Risk Patients from the CIBMTR Registry
Puntos clave
Idecabtagene vicleucel improved outcomes in relapsed/refractory multiple myeloma, particularly in high-risk patients.
Among high-risk patients, there was a notable reduction in disease progression, enhancing overall survival rates.
Observational analysis retrieved data from the CIBMTR registry on genetically and clinically defined risk categories.
Findings support the need for tailored treatments in multiple myeloma, emphasizing risks associated with patient classifications.